Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial.

ABSTRACT:

Background

Septic shock is now the leading cause of mortality in intensive care units (ICUs). Refractory septic shock requires high doses of vasopressors. Some previous studies have revealed that methylene blue could improve hypotension status and help reduce the dosage of catecholamines. This study aims to investigate the clinical effect of methylene blue in septic shock and explore whether it can increase arterial pressure and reduce the usage of vasopressors.

Methods

This study is a multicenter, randomized, placebo-controlled trial planning to include 100 refractory septic shock patients. The protocol is to administer a bolus of 2 mg/kg methylene blue intravenously followed by a continuous infusion of 0.5 mg/kg/h for 48 h. The primary outcome is the total dose of vasopres

SUBMITTER: Jia J 

PROVIDER: S-EPMC11428879 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature